Nothing said here yet.
to join the conversation.
| Templin Barry LEVP, Chief Technology Officer | Sell | 373 | $7.8K | Wed, Sep 9 |
| Waters KevinEVP, CFO | Sell | 373 | $7.8K | Wed, Sep 9 |
| Nouri AlalehEVP, CLO, CORP. SEC. | Sell | 297 | $6.2K | Wed, Sep 9 |
PROCEPT BIOROBO (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROCEPT BioRobotics has seen its share price move sharply over recent years, so the real question for you today is whether the current US$19.96 level lines up with the cash flows the business can realistically produce.
Why this governance shift at PROCEPT BioRobotics matters for investors A fresh investor lawsuit and the appointment of cardiac surgeon Dr. Michael Mack to the board put PROCEPT BioRobotics (PRCT) under a governance spotlight that stockholders will want to…
In early October 2026, PROCEPT BioRobotics added veteran cardiac surgeon Dr. Michael Mack to its board as an independent Class II director, while also facing a newly filed securities lawsuit alleging undisclosed discounting practices that inflated reported…
San Francisco, California--(Newsfile Corp. - September 4, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action...
New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox Kilsheimer LLP announces that a...
New York, New York--(Newsfile Corp. - August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ:
Wood's $498,000 purchase through a trust vehicle expands his beneficial stake to 338,103 shares as the medical robotics firm navigates losses despite $337.3 million in trailing revenue.
HYDROS revenue surged 32% amid legacy account softness and accelerated replacements.